key: cord-0914228-cyopezdr authors: Carbone, F; Montecucco, F; Twickler, ThB title: SARS‐CoV‐2: what is known and what there is to know. Focus on coagulation and lipids date: 2020-06-08 journal: Eur J Clin Invest DOI: 10.1111/eci.13311 sha: 0eb0d1d56129434849a6cfc7b1a070f66fe01f6d doc_id: 914228 cord_uid: cyopezdr As the SARS‐CoV2 pandemic is still progressing, dissemination of information has become of paramount importance. However, the rapid influx of SARS‐CoV‐2 patients in our hospitals has overwhelmed the time needed for appropriate information interpretation and its application. Noteworthy, awareness among clinicians is growing about the systemic involvement triggered by SARS‐CoV‐2 infection. Here we focused on two emerging clinical feature associated with SARS‐CoV‐2 infection with potential long‐term relevance. As the SARS-CoV2 pandemic is still progressing, dissemination of information has become of paramount importance. However, the rapid influx of SARS-CoV-2 patients in our hospitals has overwhelmed the time needed for appropriate information interpretation and its application 1, 2 . Noteworthy, awareness among clinicians is growing about the systemic involvement triggered by SARS-CoV-2 infection. Here we focused on two emerging clinical feature associated with SARS-CoV-2 infection with potential long-term relevance. Especially, coagulation disorders (in both arterial and venous vascular systems) are emerging as an important issue in SARS-CoV-2 infection. Thrombocytopenia, D-dimer elevation and prolonged prothrombin time already appeared in early reports from China 3-5 , a clinical picture similar to that could be observed in previous SARS-CoV-1 and MERS-Cov-1 pandemics, 6 . Many, signs and symptoms of severe SARS-CoV-2 infection are indeed referable to such a fibrinolysis shutdown, which may determine venous thromboembolism (VTE), complement-mediated thrombotic microangiopathies (TMA) and disseminated intravascular coagulation (DIC) 7, 8 . Endothelial dysfunction and microvascular thrombosis are the key players in VTE and TMA and this is true also for SARS-CoV-2 infection. Different vascular cell types may trigger complement cascade activation: cardiomyocytes, endothelial cells macrophages, fibroblast smooth muscle cells and pericytes. Among them, the higher and specific expression of angiotensinconverting enzyme 2 has been found in pericytes, a type of perivascular mural cells that spread outside the endothelium of capillary and part of venules. This suggests that pericytes may trigger complement cascade activation -and then VTE and TMA -as leading SARS-CoV-2 virus targeted host cell 9 . In parallel, coagulation cascade with thrombin generation are activated by proinflammatory cytokines (e.g. tumour necrosis factor [TNF]-α and interleukin (IL)-1β and -6), a process known as immunothrombosis or thromboinflammation. However, the boundary between adaptive and defective haemostasis is extremely blurred and highly dependent of how strong the cytokine storm is 7 . Especially the finding of increased Ddimer levels -a fibrin degradation product used at initial screening for venous thromboembolism (VTE) -has prompted questions regarding the relationship between SARS-CoV-2 infection and VTE. High prevalence of VTE characterizes patients with SARS-CoV-2 infection and is associated with adverse outcome, mainly due to ventilation- This article is protected by copyright. All rights reserved perfusion mismatch secondary to pulmonary embolism (PE) [10] [11] [12] [13] . Noteworthy, PE has been found as first sign of SARS-CoV2 infection even in patients with no early evidence of virus at nasal-pharyngeal swab -but later recognized by further swab, serology testing or PCR on bronchoalveolar lavage fluid - [14] [15] [16] , as also observed in our experience 28 have been reported worldwide. However, the urgency of pandemic did not allow to characterize such SARS-CoV-2-related TMA. Even mortality risk associated with such complications cannot be crearly stratified. It is likely that some inherited factor contribute to triggering TMA 29 , whereas worse outcome is related to general risk factors as reported for overall SARS-CoV-2-related mortality (e.g. sex, diabetes, obesity). Newborns and children are particular settings of patients, who seems to have less infection risk and relatively milder clinical symptoms compared to infected adults. Despite rare, coagulation disorders may affect them as expression of a multisystem inflammatory syndrome (e.g. Kawasaki disease) and then with different pathophysiological features than adults This article is protected by copyright. All rights reserved UFH and LMWH previously demonstrated limited efficacy for the treatment of sepsisinduced TMA and no data are still available for of SARS-CoV-2 infection. Instead, clinical improvement has been reported after off-label use of complement inhibitor eculizumab but randomized clinical trials testing this drug and the other C5 inhibitor ravulizumab are needed 21, 30 . Further molecules that might be considered as an attractive approach to reduce SARS-CoV-2 microthrombosis, lung injury, and associated poor outcomes. Indeed, after infiltrating the endothelium different players take part as rate-limiting steps in the inflammation-coagulation cascade. Among the other, thrombin, coagulation factor Xa or proteinase-activated receptors (PARs), especially PAR-1. are already well-studied in research and development programs concerning future treatments in thromboembolic disease 31 . The link with SARS-CoV-2-related mortality in patients with prior cardiovascular disease represents a more elusive aspect that still deserves to be investigated. Early reports from China provide conflicting results. Although this subset of patients displayed an increased mortality when admitted in the hospital for SARS-CoV-2 infection, the presence of a prior coronary heart disease did not reveal a significant odds ratio (in contrast to D-dimer levels and an older age) 4 . A further study better focusing on lipid profile similarly failed to provide any significant association 32 . Especially concerning lipid profile, those results are in contrast with previously reported in patients during seasonal influenza epidemic 33 , or various (bacterial) infections 34 . Also a large pooled data analysis (including data from MRFIT, Framingham, NORA cohorts, and other) show that respiratory disease accounted for 4% of total mortality with an inverse relationship between total cholesterol and noncancer non-cardiovascular death, subcategory respiratory diseases death 35 At the moment, patients (for instance, those with familial hypercholesterolemia) who are already treated with a statin, and subsequently present with a symptomatic SARS-CoV-2 This article is protected by copyright. All rights reserved infection, are advised not to discontinue their statin therapy 37 . This recommendation may be explained by the need to prevent atherosclerotic plaque instability induced by cytokine storm. Anyway, the wash-out time for a statin will usually take several weeks, while the evolution of SARS-CoV-2 infections during the first three days after admission will predominantly predictive of its outcome. In addition, there are incoherent data about the protective effect of statins in relation to influenza associated pneumonia. One should be careful in clinic using some statins -especially simvastatin -in combination with antiviral drugs. In the pathophysiology of SARS-CoV-2, a generalized infiltration of the endothelium (vasculature) with viral elements is found with a subsequent pronounced local inflammation 38 . Theoretically, it could be assumed that predisposing factors could make the endothelium more vulnerable for SARS-CoV-2 infiltration and damage. As reported above, SARS-CoV-2 patients with troponin levels in the higher range (and less favourable outcomes) have higher triglyceride levels and -hypothetically -an overflow of circulating triglycerides with detrimental effect on endothelial biology, especially in the post-prandial state. Indeed, triglyceride rich particles (TRPs), especially when abundant in bloodstream may induce local inflammation (e.g. TNF-α and IL-6), activation of complement and coagulation cascade, ultimately promoting endothelial dysfunction 39, 40 . It should be noticed that people living in the Western World eat mostly at least three times a day and therefore they could be considered being in a continuous postprandial state. Moreover, in patients who are obese (and those with a diabetes), both VLDL production by the liver is increased (due to the insulin resistance) and the influx of chylomicrons during the day (postprandial lipemia) will make significantly accumulate TRPs in circulation with an increased paracrine effect on the vasculature 41 . Factors (such as the anaesthetic, etomidate) that could reduce clearance of TRPs from circulation -for instance by lessening of function from key enzymes that play a role in postprandial lipid homeostasis -could therefore give rise to a more aggravated postprandial lipemia. Such a pre-coating of the endothelium by TRPs may therefore lead to a more available endothelium for SARS-CoV-2 virus spread 42 . Against this background, other prior observations could become important again; SARS-CoV-2 infection gives indeed more complications among black people (racial disparity), likely This article is protected by copyright. All rights reserved due from ethnic-dependent differences in nitric oxide generation and paracrine recovery from oxidative stress. When acute phase of SARS-CoV-2 infection is considered, a maximal synthesis and secretion of cortisol by the adrenal gland occurs. Adrenal uptake of cholesterol is not mediated by the LDL-receptor but is mostly Apo-AI SR-BI facilitated. Accordingly, apo-A1 deficiency is characterized by an impaired steroidogenesis 43 . Although, any relationship between SARS-CoV-2 Apo-A1 levels or SR-BI polymorphisms has been investigated, potential effects on steroidogenesis may have a role in modulating the cytokine storm and then clinical outcome in patients with severe SARS-CoV-2 infection. In conclusion, clinical implications of the systemic involvement triggered by SARS-CoV-2 infection may be considered the next clinical challenge once lockdown measures will have contained the outbreak shock. As the stress on intensive therapies is easing, there is an increasing need to focus on asymptomatic SARS-CoV-2 infection, which should not be limited to its infectivity but extended to potential unrecognized clinical features and long term effects/normalization of coagulation and lipid disorders. In this regard some interesting insight might come from the study of liver function, which has been so far poorly investigate but physiologically involved in lipid and coagulation pathways 44 . Coronavirus disease 2019: the harms of exaggerated information and nonevidence-based measures The novel Chinese coronavirus (2019-nCoV) infections: Challenges for fighting the storm Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Clinical Characteristics of Coronavirus Disease 2019 in China. The New England journal of medicine Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past COVID-19 and its implications for thrombosis and anticoagulation Severe COVID-19 infection and thrombotic microangiopathy: success doesn't come easily. British journal of haematology The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovascular research Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis research Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thrombosis research Deep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: Prevalence, Risk Factors, and Outcome. Circulation Acute pulmonary embolism in a patient with COVID-19 pneumonia. Diagnostic and interventional imaging COVID-19 pneumonia with hemoptysis: Acute segmental pulmonary emboli associated with novel coronavirus infection. The American journal of emergency medicine Autopsy Findings and Venous Thromboembolism in Patients With COVID-19. Annals of internal medicine COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Inhibition of inflammation induced shedding of the endothelial glycocalyx with low molecular weight heparin Identification of a heparosan heptasaccharide as an effective anti-inflammatory agent by partial desulfation of low molecular weight heparin. Carbohydrate polymers Will Complement Inhibition be the New Target in Treating COVID-19 Related Systemic Thrombosis? Circulation Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction An Italian multicenter retrospective-prospective observational study on neurological manifestations of COVID-19 (NEUROCOVID) Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology Kidney involvement in COVID-19 and rationale for extracorporeal therapies Immune Thrombocytopenic Purpura in a Patient with Covid-19. The New England journal of medicine Simultaneous Onset of COVID-19 and Autoimmune Hemolytic Anemia. British journal of haematology Autoimmune hemolytic anemia associated with Covid-19 infection. British journal of haematology Evans syndrome in a patient with COVID-19. British journal of haematology More on COVID-19 coagulopathy in Caucasian patients Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. European review for medical and pharmacological sciences COVID-19 cytokine storm: the interplay between inflammation and coagulation. The Lancet Respiratory medicine Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection Cohort study of serum total cholesterol and in-hospital incidence of infectious diseases Fatal adenovirus type 7b infection in a child with Smith-Lemli-Opitz syndrome Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic Endothelial cell infection and endotheliitis in COVID-19 Elevated remnant-like particle cholesterol concentration: a characteristic feature of the atherogenic lipoprotein phenotype Accepted Article This article is protected by copyright. All rights reserved 40 The vascular implications of postprandial lipoprotein metabolism Hepatic insulin resistance both in prediabetic and diabetic patients determines postprandial lipoprotein metabolism: from the CORDIOPREV study Postprandial Circulating miRNAs in Response to a Dietary Fat Challenge Genetic variant of the scavenger receptor BI in humans. The New England journal of medicine Liver injury in COVID-19: The current evidence. United European gastroenterology journal This article is protected by copyright. All rights reserved Increase in capillary growth from adventitial layer endothelium media layer Proinflammatory cytokines→complement activation→ coagulation cascade→ DIC Predisposing factors for endothelium dysfunction, such as: TRP, FFAs, environmental factors (air pollution), and race related nitric oxide synthesis